F18.15 Inhalant abuse with inhalant-induced psychotic disorder

Name of the Condition

• Common Name: Inhalant Abuse with Inhalant-Induced Psychotic Disorder
• Medical Term: Inhalant Abuse with Inhalant-Induced Psychotic Disorder

Summary

Inhalant abuse with inhalant-induced psychotic disorder involves the intentional misuse of inhalants—substances that produce chemical vapors—to achieve psychoactive effects, accompanied by the development of psychotic symptoms. This condition combines substance-related misuse with psychotic features, such as delusions or hallucinations, directly attributable to inhalant use. It can lead to acute intoxication, dependence, and significant physical or psychological harm, impacting an individual's health and daily functioning.

Causes

Inhalant abuse is primarily driven by the repeated misuse of inhalants for their psychoactive effects. Inhalants are often everyday household or industrial products, such as glue, paint thinners, aerosols, or solvents. The misuse of these substances can lead to dependence and, in some cases, induce psychotic symptoms due to their neurotoxic effects on the central nervous system.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive inhalant use.
• Coordination problems, dizziness, or lethargy.
• Unexplained behavioral changes such as aggression or mood swings.
• Cognitive impairment or memory issues.
• Psychotic symptoms like delusions, hallucinations, or disorganized thinking.

Diagnosis

Clinical evaluation including a detailed history of inhalant use, physical examination, and assessment of symptoms. Laboratory tests may be used to detect inhalant exposure or related complications. Psychiatric assessment is necessary to confirm the presence of psychotic symptoms and their direct association with inhalant use, ruling out other causes of psychosis.

Treatment Options

Treatment typically involves cessation of inhalant use, often supported by behavioral therapies or counseling. Medications may be used to manage withdrawal symptoms or psychotic features. Long-term care may include ongoing therapy, support groups, or rehabilitation programs to address dependence and prevent recurrence.

Prognosis and Follow-Up

Prognosis depends on the severity of use, presence of psychotic symptoms, and response to treatment. Early intervention improves outcomes, but psychotic symptoms may persist or recur. Regular follow-up is essential to monitor for relapse, manage symptoms, and adjust treatment as needed.

Complications

• Persistent cognitive impairment or memory issues.
• Worsening of psychotic symptoms.
• Physical health problems related to inhalant toxicity.
• Increased risk of accidents or injuries due to impaired judgment.
• Social or occupational dysfunction.

Lifestyle & Prevention

• Avoiding inhalant products and environments where they are accessible.
• Educating at-risk individuals about the dangers of inhalant misuse.
• Seeking support for substance use or mental health concerns.
• Maintaining a stable, supportive environment to reduce triggers.

When to Seek Professional Help

Seek help if experiencing intense cravings, psychotic symptoms, or difficulty stopping inhalant use. Also, consult a healthcare provider for unexplained behavioral changes, cognitive issues, or if inhalant use is interfering with daily life.

Tips for Medical Coders

Document the presence of inhalant-induced psychotic symptoms and their direct association with inhalant use. Ensure clinical details support the diagnosis, including a history of inhalant misuse and psychotic features not better explained by other conditions. Code F18.15 is appropriate when both inhalant abuse and inhalant-induced psychotic disorder are present.